Materiali ACT - Notizie dal mondo della ricerca Torna alla pagina precedente
Notizie dal mondo della Ricerca
 

I CANNABINOIDI 'RAFFREDDANO' L'INTESTINO

Cannabinoids inhibit motility and secretion in the intestine. They are now assigned the additional task of curbing excessive inflammation, suggesting that drugs targeting the endogenous cannabinoid system could be exploited for inflammatory bowel disease.
George Kunos & Pál Pacher. Cannabinoids cool the intestine Nature Medicine 10, 678 - 679 (2004)


Archivio | 1999 - 2000 -2001 |


 
Torna alla pagina precedente
PER SAPERNE DI PIU'
NAUSEA E VOMITO STIMOLAZIONE APPETITO SCLEROSI MULTIPLA TERAPIA DEL DOLORE TRAUMI CRANICI E ICTUS
SINDROME DI TOURETTE GLIOBLASTOMI ARTRITE REUMATOIDE GLAUCOMA EPILESSIA
ALLERGIE TERAPIA ANTITUMORALE ASMA BRONCHIALE MALATTIE AUTOIMMUNI MALATTIE INFIAMMATORIE INTESTINALI
MALATTIE NEURODEGENERATIVE PATOLOGIE CARDIOVASCOLARI SINDROMI ANSIOSO-DEPRESSIVE SINDROMI DA ASTINENZA LESIONI MIDOLLARI

 

    EDITORIALI E REVIEW

  1. Voth EA Medicinal Applications of Delta-9-Tetra hydrocannabinol and Marijuana Annals Internal Med 1997;126:791-798
    [FULL-TEXT]

  2. Kassirer JP. Federal foolishness and marijuana.N Engl J Med 336:366, 1997.
    [FULL TEXT]
  3. Robson P Cannabis as medicine: time for the phoenix to rise? Br Med J 316:1034, 1998
    [FULL-TEXT]

  4. House of Lords Science and Technology Committee Medical use of cannabis and cannabinoids: review of the evidence, 1998
    [FULL-TEXT]

 

 

    NAUSEA E VOMITO IN CHEMIOTERAPIA    

  1. Chang AE et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979; 91: 819-824.

  2. Frytak S et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.Ann Intern Med 1979;91:825-30.
    [ABSTRACT]

  3. Herman TS et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300: 1295-1297.

  4. Kluin-Neleman JC, Neleman FA, Meuwissen O, Maes R. Delta9-tetrahydrocannabinol (THC) as an antiemetic for patients receiving cancer chemotherapy; a double blind cross-over trial against placebo. Vet Hum Toxicol 1979; 21: 228-240.

  5. Sallan SE Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980 302: 135-138.
    [FULL-TEXT]

  6. Colls BM. Cannabis and cancer chemotherapy. Lancet 1980; i: 1187-1188.

  7. Lane M, Smith FE, Sullivan RA, Plasse TF. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 1990; 13: 480-484

  8. Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981; 21: 76-80S.

  9. Ungerleider JT Cannabis and cancer chemotherapy: a comparison of oral delta-9- tetrahydrocannabinol and prochlorperazine. Cancer 1982;50:636-45.
    [ABSTRACT]

  10. Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer chemotherapy patientthe UCLA study. Part II: patient drug preference. Am J Clin Oncol 1985; 8: 142-147.

  11. Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48: 657-663.

  12. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79: 946-952.

  13. Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981; 47: 1746-1751.

  14. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 1980; 91: 449-451.

  15. Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 1986; 3: 39-42.

  16. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61: 502-505.

  17. Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981; 21: 64-9S.

  18. George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomed Pharmacother 1983; 37: 24-27.

  19. Gralla RJ, Tyson LB, Bordin LA, Clark RA, Kelsen DP, Kris MG, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984; 68: 163-172.

  20. Hutcheon AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J, et al. A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 1087-1090.

  21. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev 1982; 9: 25-33.

  22. Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat Rev 1982; 9: 45-48.

  23. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manag 1991; 6: 352-359.

  24. Levitt M. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat Rev 1982; 9(suppl B): 49-53.

  25. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6: 243-246.

  26. Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981; 21: 38-42S.

  27. Niederle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986; 64: 362-365.

  28. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-340.

  29. Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 1980; 140: 1431-1433.

  30. Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17: 285-288.

  31. Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980; 64: 219-224.

  32. Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH, Rieth TE. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat Rev 1982; 9(Suppl B): 39-44.

  33. Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences 1995;56:2097-2102
    [ABSTRACT]

  34. M.R. Tramèr et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ, 323 (2001):16-24
    [PDF] [FULL-TEXT]

  35. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001 Feb;24(2):198-203
    [ABSTRACT]

  36. Robert Randall, ed., Marijuana, Medicine and the Law, Vol . 2 (Galen Press, Wash. DC) 1989, pp. 36ff.

  37. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta-9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974 Sep;28(1):172-7.
    [ABSTRACT]
  38. Hollister LE, Gillespie BA. Interactions in man of delta-9-THC. II. Cannabinol and cannabidiol.
    Clin Pharmacol Ther. 1975 Jul;18(1):80-3
    [ABSTRACT]
  39. - - - aggiornamenti - - -

  40. I CANNABINOIDI RINFORZANO GLI EFFETTI ANTIEMETICI DELL'ONDANSETRON
    Psychopharmacology (Berl) 2004 Jan 22
  41. RICERCA: THC EFFICACE CONTRO GLI EFFETTI COLLATERALI DELLA CHEMIOTERAPIA RESISTENTI ALLA TERAPIA CONVENZIONALE
    Hautarzt. 2006 Jan 12;
  42. IL DRONABINOL E' EFFICACE COME L'ONDANSETRON NEL TRATTAMENTO DELLA NAUSEA E DEL VOMITO DOPO CHEMIOTERAPIA
    Curr Med Res Opin 2007;23(3):533-43

 

 

    STIMOLAZIONE DELL'APPETITO IN PAZIENTI CON AIDS    

  1. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine (second edition). New Haven, CT: Yale University Press 1997 (trad. italiana Marijuana la medicina proibita, Editori Riuniti, Roma 2002 )
    [BUY IT]

  2. R. Foltin et al., Behavioral analysis of marijuana effects on food intake in humans, Pharmacology, Biochemistry and Behavior 25 (1986): 577-582.

  3. R. Foltin et al., Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory, Appetite 11 (1988): 1-14.

  4. V.Di Marzo et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822 - 825 (2001)
    [ABSTRACT]

  5. Gorter, R.; Seifried, M.; and Volberding, P. Dronabinol effects on weight in patients with HIV infection. AIDS 6:127, 1992.

  6. Struwe M et al. Effect of dronabinol on nutritional status in HIV infection. Annals of Pharmacotherapy 1993;27:827-831.

  7. Beal JE Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97
    [ABSTRACT]

  8. Mattes RD, Engelman K, Shaw LM, Elsohly MA. 1994. Cannabinoids and appetite stimulation. Pharmacology, Biochemistry and Behavior 49:187-195.

  9. Abrams DI, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003;139(4):258-266
    [FULL TEXT] [PDF]

  10. Kosel BW et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002 Mar 8;16(4):543-50
    [ABSTRACT]

  11. British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic , 1997.
    [BUY IT]
  12. - - - aggiornamenti - - -

  13. Effetti dei cannabinoidi nei pazienti HIV positivi: risultati di uno studio clinico controllato
    Abrams et al. Ann Intern Med. 2003 Aug 19;139(4):258-66.
  14. CANNABIS E ADERENZA ALLA TERAPIA ANTIRETROVIRALE NEI PAZIENTI HIV POSITIVI
    J Acquir Immune Defic Syndr 2005 Jan 1;38(1):43.
  15. I PAZIENTI SIEROPOSITIVI HANNO SOLLIEVO DALLA CANNABIS
    J Pain Symptom Manage. 2005 Apr;29(4):358-67.
  16. CANNABIS EFFICACE NEL TRATTAMENTO DELLA NEUROPATIA DA HIV
    Neurology 2007;68(7):515-21

 

 

    SCLEROSI MULTIPLA    

  1. Petro DJ, Ellenberger C. Treatment of Human Spasticity with Tetrahydrocannabinol. Journal of Clinical Pharmacology 1981;21:413-416
    [ABSTRACT]
  2. D. Clifford. Tetrahydrocannabinol for Tremors in Multiple Sclerosis. Annals of Neurology 1983;13: 669-671.
    [ABSTRACT]
  3. J. Ungerleider et al., Delta-9-THC in the treatment of Spasticity Associated with Multiple Sclerosis. Advances in Alcohol and Substnace Abuse 7 1988;7: 39-50.
  4. Greenberg HS et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clinical Pharmacology Ther 1994;55:324-328.
    [ABSTRACT]
  5. Meinck H et al., Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. Journal of Neurology 1989;226:120-122.
    [FULL TEXT]
  6. Martyn CN et al. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579
    [FULL TEXT]
  7. Consroe P et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology 1997;38(1):44-48. [ABSTRACT]
  8. Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine (second edition). New Haven,CT: Yale University Press 1997 (trad. italiana: Marijuana la medicina proibita, Editori Riuniti, Roma 2002 )
    [BUY IT]
  9. L. Dell'Osso et al. "Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis." Neurology 54 (2000): 2190-2193.
  10. National Institutes of Health, "Workshop on the Medical Utility of Marijuana: Report to the Director, " Washington, D.C. (1997).
    [PDF] [FULL TEXT]
  11. F.A. Campbell et al.Are cannabinoids an effective and safe treatment option in the mamagement of pain? A qualitative systematic review. BMJ, 323 (2001):13-18
    [PDF] [FULL TEXT]
  12. House of Lords Select Committee on Science and Technology Ninth Report, November 1998.
    [FULL TEXT]
  13. J. Joy et al., Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press (1999), Chapter 4, Section 4.26 .
    [PDF] [FULL TEXT] [BUY IT]
  14. L. Growing et al., "Therapeutic use of cannabis: clarifying the debate," Drug and Alcohol Review 17 (1998): 445-452.
  15. Baker D et al Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000;404: 84 - 87
    [ABSTRACT]
  16. A. Achiron et al. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. Journal of Neuroimmunology 2000;102: 26-31.
    [ABSTRACT]
  17. Kassirer JP. Federal foolishness and marijuana. N Engl J Med 336:366, 1997.
    [FULL TEXT]
  18. John Zajicek et al. on behalf of the UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003 Nov 8;362(9395):1517-1526.
    [ABSTRACT]

  19. Metz L, Page S. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? Lancet 2003 Nov 8;362(9395):1513
    [FULL TEXT]
  20. - - - aggiornamenti - - -

  21. IMMUNOREGOLAZIONE INDOTTA DA CANNABINOIDI NELLA SCLEROSI MULTIPLA
    J Clin Invest 2003 Apr - J Neuroimmunol 2003 Apr - J Neurosci 2003 Apr
  22. I CANNABINOIDI INIBISCONO LA NEURODEGENERAZIONE NELLA SM ?
    Pryce G, et al. Brain 2003; 126:2191
  23. LO STUDIO CAMS CONFERMA L'EFFICACIA E LA BUONA TOLLERABILITA' DEI DERIVATI DELLA CANNABIS NEL TRATTAMENTO DEI SINTOMI DELLA SCLEROSI MULTIPLA
    John Zajicek et al. Lancet 2003 Nov
  24. EFFICACIA, SICUREZZA E TOLLERABILITA' DI UN ESTRATTO DI CANNABIS SOMMINISTRATO PER VIA ORALE NEL TRATTAMENTO DELLA SPASTICITA' IN PAZIENTI CON SCLEROSI MULTIPLA
    C.Vaney et al. Multiple Sclerosis 2004, 10 ; 417
  25. EFFETTI DELLA CANNABIS SULLA SINTOMATOLOGIA DELLA SCLEROSI MULTIPLA. RISULTATI DI UNO STUDIO CONTROLLATO
    DT Wade et al. Multiple Sclerosis 2004, 10 ; 434
  26. RISULTATI A LUNGO TERMINE DELLO STUDIO CAMS: I BENEFICI MIGLIORANO NEL TEMPO
    New Scientist 10 Set 2004
  27. ITALIA: FINALMENTE AL VIA SPERIMENTAZIONE SU CANNABIS E SCLEROSI MULTIPLA
    26.09.04 - Genova
  28. ESTRATTI DI CANNABIS EFFICACI NEL DOLORE DI ORIGINE CENTRALE NELLA SCLEROSI MULTIPLA
    Neurology. 2005 Sep 27;65(6):812-9.
  29. LA CANNABIS RIDUCE L'INCONTINENZA ASSOCIATA ALLA SCLEROSI MULTIPLA
    Int Urogynecol J Pelvic Floor Dysfunct 2006 Mar 22
  30. SATIVEX EFFICACE CONTRO LA SPASTICITÀ IN PAZIENTI CON SCLEROSI MULTIPLA
    Eur J Neurology 2007;14(3):290-296
  31. Efficacia a lungo termine del Sativex nel dolore neuropatico
    Clin Ther 2007;29(9):2068 79.

 

 

    TERAPIA DEL DOLORE    

  1. O'Shaughnessy WB. On the preparations of the hemp, or gunjah (Cannabis indica): the effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans. of the Med. and Phys. Society of Bengal (1838-40):421-61

  2. Benigni R , Capra, Cattorini. Erbe medicinali: chimica, farmacologia e terapia. Milano (1962) 214

  3. Lichtman AH and Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258 (1991): 517-23
    [ABSTRACT]

  4. Tsou K et al. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70 (1996): 791-8
    [ABSTRACT]

  5. Smith FL. et al. Characterization of delta9- tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rat. Pharmacol. Biochem. Behav.60 (1998): 183-91
    [ABSTRACT]

  6. Welburn PJ et al. Effects of cannabinoids on the abdominal constriction response in mice: within cannabinoid interaction. Psychoparmacology 46 (1976): 83-5
    [ABSTRACT]

  7. Neeleman PMP. Effects of delta9 - tetrahydrocannabinol and other cannabinoids on pain. E.S.A. Annual Meeting Vienna (2000): 139-42

  8. Mason DJ Jr et al. Cannabinoid modulation of dynorphin A : correlation to cannabinoid-induced antinociception. Eur. J. Pharmacol. 381 (1999): 105-11
    [ABSTRACT]

  9. Hohmann AG et al. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid Win 55.212-2. Life Science 56 (1995): 2111-18
    [ABSTRACT]

  10. Richardson JD et al. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Neuroscience 18 (1998): 451-7
    [PDF] [FULL TEXT]

  11. Richardson JD et al. Cannabinoids Reduce Hyperalgesia and Inflammation via Interaction with Peripheral CB1 Receptors. Pain 1998;(75)1:111-119
    [ABSTRACT]

  12. Martin JW et al. Spinal cannabinoids are anti-allodynic in rats with persistent infiammation.Pain 82 (1999): 199-205)
    [ABSTRACT]

  13. Meng ID et al. An analgesia circuit activated by cannabinoids.Nature 394 (1998): 277-81
    [ABSTRACT]

  14. Walker JM et al. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci USA 96 ( 1999): 12198-203
    [PDF] [FULL TEXT]

  15. Coluzzi F, Mattia C. I cannabinoidi nel dolore. Pathos 2002; 4(9)114-124
    [FULL TEXT]

  16. Calignano A et al. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) : 277-81
    [ABSTRACT]

  17. Ko MC, Woods JH. Local administration of D9-tetrahydrocannabinol attenuates capsaicin induced thermal nociception in Rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology 143(1999):322-6
    [ABSTRACT]

  18. Noyes R et al. The analgesic properties of D9- tetrahydrocannabinol and codeine. Clin. Phar. Ther. 18 (1975): 84-9
    [ABSTRACT]

  19. Cichewicz DL et al. Enhancement of µ Opioid Antinociception by Oral delta9-Tetrahydrocannabinol: Dose-Response Analysis and Receptor Identification.J. Pharmacol. Exp. Ther. 289 (1999): 859-67
    [PDF] [FULL TEXT]

  20. Campbell FA et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323 (7 July): 1-6
    [PDF] [FULL TEXT]

  21. Ethan Russo, Leslie Iversen, Denis J Petro, Franjo Grotenhermen, Fiona A Campbell, Andrew Moore, Henry J McQuay, Dawn Carroll, Martin R Tramèr, and D John M Reynolds [Letters] Cannabinoids in pain management BMJ 2001;323:1249 ( 24 November )
    [FULL TEXT]

  22. Bianchi M. Effetti antiemetici ed analgesici dei cannabinoidi.In: Atti del convegno: "Usi innovativi di farmaci antichi. L'attuale rivalutazione della cannabis e dei cannabinoidi." Università "La Sapienza", Roma, 6-10-2001.
    [ABSTRACT]

  23. Russo EB. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 1998:76(1-2):3-8.
    [ABSTRACT]

  24. Herzberg U et al. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat of neuropathic pain. Neurosci Lett 221(2-3)157-60, 1997.

  25. Mazzari S et al. N-(2-Hydroxyethil)hexadecanamide reduces mechanical hyperalgesia following sciatic nerve constriction injury.Soc. Neurosci. Abstr.21, 652,1995.

  26. Zeltser R et al. Suppression of neuropathic pain behaviour in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain 47,95-103, 1991.

  27. Fox A et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.Pain 92, 91-100, 2001.

  28. Bridges D et al. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133, 586-94, 2001.

  29. F. Grotenhermen, R. Huppertz. La canapa come medicina. Leoncavallo libri, Milano 1999, pp. 77-79 (traduzione italiana di "Hanf als Medizin" 1997)

  30. Chatterjee A et al. A dramatic response to ihhaled cannabis in a woman with central thalamic pain and dystonia. J pain Symptom Manage 24(1), 4, 2002.

  31. Frank B, Kapur D. Further experience with nabilone. Presented at the annjual scientific meeting of the pain society of Great Britain, april 2001.

  32. Notcutt W et al. Medicinal cannabis extract in chronic pain :design of a comparative " n of 1” primary study. IRCS annual symposium on the cannabinoids, Abstr. 2002.

  33. Williamson, E.M., Evans, F.J., “Cannabinoids in Clinical Practice”, Drugs, vol. 60, 2000, pp. 1303-1314.

  34. Campbell FA et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323 (7 July): 1-6
    [PDF] [FULL TEXT]

  35. J. Joy et al., Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press (1999), Chapter 4, Section 4.26 .
    [PDF] [FULL TEXT] [BUY IT]
  36. House of Lords Science and Technology Committee Medical use of cannabis and cannabinoids: review of the evidence, 1998
    [FULL-TEXT]

  37. ...[inserire voci dolore tumorale]

  38. Gieringer D. Medical use of cannabis: Experience in California. In Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential, edited by F. Grotenhermen and E.B. Russo. Binghamton, NY: The Haworth Press, Inc. (2002).

  39. Schnelle M et al. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forschende Komplementarmedizin 1999;(Suppl 3):28.36.
    [ABSTRACT]

  40. Horstman J. Marijuana As Medicine. Arthritis Today Magazine, 2000 Vol.14, n. 6

  41. Curatolo M, Bogduk N. Pharmacological pain treatment of musculoskeletal disorders: current perspectives and future prospects. Clin J Pain 17 (1) 25-32, 2001.

  42. Fishbain DA et al. Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria. Pain. 1986 Aug;26(2):181-97.
    [ABSTRACT]

  43. E. Carlini et al. Hypnotic and Antiepileptic Effects of Cannabidiol. Journal of Clinical Pharmacology 21 (1981): 417S-427S
    [ABSTRACT]

  44. Volfe Z et al. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. International Journal of Clinical Pharmacology Research 1985;5(4):243-6.
    [ABSTRACT]

  45. Boger Dl et al. Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid olemide. Proc Natl Acad Sci USA 95(8): 4102-7.
    [ABSTRACT]

  46. McPartland JM. Cannabis and Eicosanoids: A Review of Molecular Pharmacology. Journal of Cannabis Therapeutics 2001;1(1) 71-83.
    [ABSTRACT]

  47. Meng ID et al. An analgesia circuit activated by cannabinoids. Nature 1998; 395(6700):381-3.
    [ABSTRACT]

  48. Lichtman AH et al. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidences supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996;276(2):585-593.
    [ABSTRACT]

  49. Stefano GB et al. Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 1997;763(1):63-8.
    [ABSTRACT]

  50. Shen M, Thayer SA. Delta-9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 1999;55(1):8-13.
    [FULL TEXT]

  51. El-Mallack RS. Marijuana and migraine. Headache 1987; 27(8):442-3.
    [ABSTRACT]

  52. Grinspoon L, BakalarJB. Marijuana, the forbidden medicine.New Haven, CT: Yale University Press, 1997. (Trad. italiana: "Marijuana, medicina proibita". Milano, Franco Muzzio editore 1997)

  53. Mikuriya TH. Chronic migraine headache: Five cases successfully treated with Marinol and/or illicit cannabis, 1997.
    [FULL TEXT]

  54. Petro D. Spasticity and chronic pain. In Mathre ML, ed. Cannabis in medical practice. Jefferson, NC: McFarland, 1997.

  55. Schnelle M et al. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forschende Komplementarmedizin 1999;(Suppl 3):28.36.
    [ABSTRACT]

  56. Gieringer D. Medical use of cannabis: Experience in California. In Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential, edited by F. Grotenhermen and E.B. Russo. Binghamton, NY: The Haworth Press, Inc. 2002.

  57. Russo EB. Hemp for headache. An in-depth historical and scientific review. Journal of Cannabis Therapeutics, 2001;1(2):21-92.
    [PDF]

  58. Russo EB. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review.Pain 1998:76(1-2):3-8.
    [ABSTRACT]

- - - aggiornamenti - - -

  • SPECIALISTI DI TUTTO IL MONDO DISCUTONO SUGLI EFFETTI ANALGESICI DELLA CANNABIS
    August 17-22, 2002
  • UK: AL VIA UNO STUDIO SUL DOLORE POST-OPERATORIO
    BBC News 20 Agosto 2003
  • L'ANANDAMIDE INIBISCE IL RILASCIO DI MEDIATORI DEL DOLORE NEUROPATICO
    Life Sci 2003 Sep 19;73(18):2345-53
  • EFFETTI ANALGESICI DEL CANNABINOIDE CT-3 NEL DOLORE NEUROPATICO
    JAMA. 2003;290:1757-1762
  • I DERIVATI DELLA CANNABIS RIDUCONO IL DOLORE NEUROPATICO NEI PAZIENTI CON SINDROME DEL PLESSO BRACHIALE
    Anaesthesia, 2003;58:938
  • RUOLO DEI RECETTORI CANNABINOIDI NELL'EMICRANIA
    Pharmacol Exp Ther. 2004 Jan 12
  • CONFERME AL RUOLO DEI CANNABINOIDI NELLA TERAPIA DEL DOLORE
    Anaesthesia 2004 May;59(5):440-52
  • DIMOSTRAZIONE DI EFFICACIA DEL SATIVEX® NEL DOLORE NEUROPATICO
    15.06.04
  • CANNABIS E DOLORE, PARTE IN CANADA LO STUDIO COMPASS
    Bollettino IACM 19.12.2004
  • ESTRATTI DI CANNABIS ALLEVIANO IL DOLORE INTRATTABILE
    Pain 2004 Dec;112(3):299
  • RISULTATI POSITIVI CON IL SATIVEX® NEL DOLORE TUMORALE
    Comunicato stampa GW Pharm 19/01/2005
  • ITALIA: PRESTO AL VIA SPERIMENTAZIONE SU CANNABIS E TERAPIA DEL DOLORE
    ADN Cronos Salute 26-31 gennaio 2005
  • IL THC RIDUCE IL DOLORE DOVUTO ALLA FIBROMIALGIA
    Curr Med Res Opin 2006;22(7):1269-1276
  • NABILONE EFFICACE NEL TRATTAMENTO DEL DOLORE CRONICO
    Wien Klin Wochenschr 2006;118(11-12):327-35)
  • Cannabis e cannabinoidi nelle cure palliative
    La Rivista Italiana di Cure Palliative 2009; 2: 40-64
  • Efficacia del Sativex nella terapia del dolore tumorale
    J Pain Symptom Manage. 2009 Nov 4
  •  

     

      TRAUMI CRANICI / ICTUS    

    1. Panikashvili D, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001 Oct 4;413(6855):527-31.
      [ABSTRACT]

    2. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications.Trends Mol Med. 2002 Feb;8(2):58-61.
      [ABSTRACT]

    3. Hampson, A., "Cannabinoids as Neuroprotectants against Ischemia", in: Grotenhermen, F., Russo, E.B., (a cura di), Cannabis and cannabinoids. Pharmacology, Toxicology and Therapeutic Potential, Binghamton, NY, Haworth Press, 2002, p. 101-110.

    4. Nagayama T et al. Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures. J. Neurosci. 1999; 19(8): 2887-2895.
      [PDF] [FULL TEXT]

    5. van der Stelt, M et al. Neuroprotection by delta9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity. J. Neurosci. 2001; 21(17): 6475, 2001
      [PDF] [FULL TEXT]

    6. Hampson AJ, Grimaldi M et al. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci 1998;95(14):8268-8273
      [PDF] [FULL TEXT]

    7. Hampson A.J., Grimaldi M. Neuroprotective Antioxidants from Marijuana. Ann N Y Acad Sci 2000;899:274-82
      [ABSTRACT]

    8. Fishman R. Cannabinoid is neuroprotective in head traumaLancet 1998;352
      [ABSTRACT]

    9. Knoller, N., et al., "Dexanabinol in the Treatment of Severe Closed Head Injury: A Randomized, Placebo-controlled, Phase II Clinical Trial. Crit Care Med 2002 Mar;30(3):548-54
      [ABSTRACT]
    10. - - - aggiornamenti - - -

    11. CONCLUSA SPERIMENTAZIONE SU DEXANABINOL NEI TRAUMI CRANICI
      comunicato Pharmos 15.03.04
    12. DEXANABINOL INEFFICACE NEI TRAUMI CRANICI
      Comunicato stampa Pharmos Corp. 20.12.04
    13. IL CBD PROTEGGE DALL’INFARTO CEREBRALE
      Stroke. 2005 May;36(5):1077-82.

     

     

      SINDROME DI TOURETTE    

    1. Sandyk R. Awerbuch G. Marijuana and Tourette's syndrome. J Clin Psychopharmacol 1988; 8: 444 - 445
      [FULL TEXT]

    2. Muller-Vahl KR et al. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:3, 1999.
      [ABSTRACT]

    3. Muller-Vahl KR et al. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001; 34(1):19-24.
      [ABSTRACT]

    4. Mueller-Vahl K, et al. Treatment of Tourette-Syndrome with delta-9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002 Mar;35(2):57-61
      [ABSTRACT]

    5. M. Stuhrmann, D. Gadzicki, K. Mueller-Vahl. A mutation in the human cannabinoid receptor (CNR1) gene in patients with Gilles de la Tourette syndrome. FASEB 229
      [ABSTRACT]
    6. - - - aggiornamenti - - -

    7. CONFERME SUL RUOLO DEL THC NELLA SINDROME DI TOURETTE
      J Clin Psychiatry 2003;64(4):459-465

     

     

      GLIOBLASTOMI    

    1. Sanchez C et al Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998;436(1):6-10
      [ABSTRACT]

    2. Galve-Roperph I et al. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and ERK activation. Nature Medicine 6, 313-319 (2000);
      [ABSTRACT]

    3. Sanchez C, et al. Inhibition of Glioma Growth in Vivo by Selective Activation of the CB(2) Cannabinoid Receptor. Cancer Res 2001;61(15):5784-5789
      [PDF] [FULL TEXT]

    4. Gonzalez-Feria, L., Department of Neurosurgery, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spagna. Comunicazione privata, 2002.
    5. - - - aggiornamenti - - -

    6. I CANNABINOIDI INIBISCONO LA NEOANGIOGENESI NEI GLIOMI MALIGNI
      FASEB J. 2003 Mar;17(3):529-31.
    7. IL CANNABIDIOLO INIBISCE LA CRESCITA DEI GLIOMI
      J Pharmacol Exp Ther. 2003 Nov 14
    8. I CANNABINOIDI INIBISCONO L'ANGIOGENESI NEI TUMORI CEREBRALI
      Blázquez et al. Cancer Research 64, 5617-5623, August 15, 2004
    9. IL THC SPERIMENTATO CONTRO I TUMORI CEREBRALI IN UNO STUDIO CLINICO PILOTA
      Br J Cancer, 2006 Jun 27

     

     

      ARTRITE REUMATOIDE    

    1. Klein TW, Newton CA, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998;19:373-80.
      [ABSTRACT]

    2. Klein TW, Newton CA, Friedman H. Cannabinoids and the immune system. Pain Res Manag. 2001;6:95-101.
      [ABSTRACT]

    3. McPartland JM. Cannabis and eicosanoids: a review of molecular pharmacology. J Cann Ther 1(1) 71-83, 2001a.

    4. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? J Cann Ther 1(3-4), 103-32, 2001b.

    5. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burnstein SH. Dimethylheptyl-THC-11 OIC Acid: A Nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis and Rheumatism 1998;41:163-170.
      [ABSTRACT]

    6. Bidinger B, Burnstein SH, Furse RK, Rossetti RG, Zurier RB. Suppression of human monocyte interleukin-1 production by ajulemic acid (CT3), a nonpsychoactive cannabinoid. IRCS annual symposium on the cannabinoids, July 2002

    7. Bianchi G., Ospedale "La Colletta", Arenzano, Genova. Comunicazione privata. 2002.

    8. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulan R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 2000;97:9561-6
      [PDF] [FULL TEXT]
    9. - - - aggiornamenti - - -

    10. EFFICACIA DI ESTRATTI DI CANNABIS NEL TRATTAMENTO DEL DOLORE ASSOCIATO ALL'ARTRITE REUMATOIDE
      Comunicato stampa GW Pharm 09.06.04
    11. ESTRATTO DI CANNABIS EFFICACE NEL TRATTAMENTO DELL’ARTRITE REUMATOIDE
      Rheumatology 2005 Nov 9

     

      GLAUCOMA    

    1. Hepler et al. Marihuana Smoking and Intraocular Pressure, JAMA, 1971 Sep 6;217(10):1392.
      [ABSTRACT]

    2. Merritt J et al. Effect of Marihuana on Intraocular and Blood Pressure in Glaucoma. Ophthalmology 1980;87: 222-228
      [ABSTRACT]

    3. Pate DW et al. Effects of topical anandamides on intraocular pressure in normotensive rabbits Life Sci 1996;58(21):1849-60
      [ABSTRACT]

    4. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem 1997;40(18):2793-809
      [ABSTRACT]

    5. Porcella et al. Cannabinoid receptor CB mRNA is highly expressed in the rat ciliary 1 body: implications for the antiglaucoma properties of marihuana . Molecular Brain Research 58 1998 240–245
      [PDF]

    6. Straiker et al. Localization of Cannabinoid CB1 Receptors in the Human Anterior Eye and Retina. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2442-8.
      [ABSTRACT]

    7. Porcella et al. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci. 2000 Mar;12(3):1123-7
      [PDF]

    8. Porcella et al. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur J of Neurosci, Vol. 13, pp. 409-412, 2001.
      [PDF]
    9. - - - aggiornamenti - - -

    10. I CANNABINOIDI PROTEGGONO IL NERVO OTTICO DALLA NEUROTOSSICITA'
      Am J Pathos 2003; 163 [5]: 1997-2008

     

      EPILESSIA    

    1. Consroe PF et al. Anticonvulsant Nature of Marihuana Smoking JAMA 1975; 234:306-307

    2. [ABSTRACT]

    3. Cunha JM et al. Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients. Pharmacology 1980;21:175-185

    4. [ABSTRACT]

    5. Ames FR. . Anticonvulsant effect of cannabidiol. South African Medical Journal 1986; 69:14.

    6. [ABSTRACT]

    7. Trembly B, Sherman M. 1990. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Unpublished manuscript presented at the Marijuana '90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete, July 8-11.
      Reviewed in Consroe P, Sandyk R. 1992. Potential role of cannabinoids for therapy of neurological disorders. In: Bartke A, Murphy LL, Editors, Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, FL: CRC Press. Pp. 459-524.
    8. B. Zimmerman et al., "Is Marijuana the Right Medicine for You?" A Factual Guide to the Medical Uses of Marijuana, New Canaan, CT: Keats Publishing, 1998.

    9. [BUY IT]

    10. S. Ng et al. Illicit drug use and the risk of new-onset seizures. American Journal of Epidemiology 1990;132: 47-57.

    11. [ABSTRACT]

    12. National Institutes of Health, "Workshop on the Medical Utility of Marijuana, Report to the Director" Washington, D.C.,1997.

    13. [PDF] [FULL TEXT]

    14. House of Lords Select Committee on Science and Technology Ninth Report, Chapter 5, Section 5.31.. London, 1998

    15. J. Joy et al.,"Marijuana and Medicine: Assessing the Science Base. Table 4.4: Clinical Trails of Cannabinoids in Epileptics. Washington D.C.: National Academy Press, 1999.
    16. - - - aggiornamenti - - -

    17. CONFERME SUL RUOLO DEI CANNABINOIDI NEL CONTROLLO DELLE CONVULSIONI
      J Pharmacol Exp Ther.2003; 307: 129-137
    18. I CANNABINOIDI PROTEGGONO I NEURONI CONTRO LA ECCITO-TOSSICITA'
      Science Oct 3 2003: 84-88
    19. RUOLO DEGLI ENDOCANNABINOIDI NEL CONTROLLO DELL’ECCITABILITÀ NEURONALE E DELLE CRISI EPILETTIFORMI
      Biochemical Pharmacology 68, 1691-8, 2004
    20. EFFETTI ANTIEPILETTICI DELLA N-PALMITOILETANOLAMIDE
      Epilepsia 45:1184-1188,2004.

     

     

      TERAPIA ANTITUMORALE    

    1. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. (1975) 55:597-602.
      [ABSTRACT]
    2. De Petrocellis L et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences 95 (1998): 8375-8380.
      [PDF] [FULL TEXT]
    3. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. (2001) 358:249-255.
      [PDF] [FULL TEXT]

    4. Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000;141:118-126.
      [PDF] [FULL TEXT]

    5. Sanchez C et al. Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998;436(1):6-10
      [ABSTRACT]

    6. Galve-Roperh I et al. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation of ERK activation. Nature Medicine 2000 Mar;6(3):313-9
      [ABSTRACT]
    7. Sanchez C et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001 61:5784-5789.
      [ABSTRACT]

    8. McKallip RJ et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100, 627-634
      [PDF] [FULL TEXT]

    9. Bifulco M et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. (2001) 15:2745-2747
      [PDF] [FULL TEXT]

    10. Baek S et al. Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21 (1998): 353-356
      [ABSTRACT]
    11. Casanova ML et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation, 111:43-50, January 1, 2003.
      [PDF] [FULL TEXT]

    12. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: A call for further research. Nature Medicine 2002; 8 (6):547- 550
      [PDF]

    13. Tramer et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Brit Med J. (2001) 323:16-21.
      [PDF] [FULL-TEXT]

    14. Zhu LX et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. (2000) 165:373-380
      [PDF] [FULL TEXT]
    15. - - - aggiornamenti - - -

    16. I CANNABINOIDI INIBISCONO LA NEOANGIOGENESI NEI GLIOMI MALIGNI
      FASEB J. 2003 Mar;17(3):529-31.
    17. IL RUOLO POTENZIALE DEGLI ENDOCANNABINOIDI NEL CONTROLLO DELLA CRESCITA DEL CARCINOMA COLORETTALE
      Gastroenterology. 2003 Sep;125(3):677-87.
    18. IL CANNABIDIOLO INIBISCE LA CRESCITA DEI GLIOMI
      J Pharmacol Exp Ther. 2003 Nov 14
    19. IL THC RIDUCE LA CAPACITÀ REPLICATIVA DI ALCUNI VIRUS ERPETICI ONCOGENI
      Medveczky MM et al, BMC Medicine, 2004; 2:34
    20. I CANNABINOIDI INIBISCONO L'ANGIOGENESI NEI TUMORI CEREBRALI
      Blázquez et al. Cancer Research 64, 5617-5623, August 15, 2004
    21. IL THC SPERIMENTATO CONTRO I TUMORI CEREBRALI IN UNO STUDIO CLINICO PILOTA
      Br J Cancer, 2006 Jun 27

     

      MALATTIE AUTOIMMUNI    

    1. Cabral G.A. (2002). Immune system. In: Grotenhermen F. - Russo E.B. (eds) Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: Haworth Press 2002, p. 285-294.

    2. Melamede R. (2002) Possible mechanisms in autoimmune disease. In: Grotenhermen F.- Russo E.B. (eds) Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. Binghamton, NY: Haworth Press 2002, p. 111-119.

     

     

      MALATTIE INFIAMMATORIE CRONICHE INTESTINALI    

    1. B. Zimmerman et al., "Is Marijuana the Right Medicine for You?" A Factual Guide to Medical Uses of Marijuana, New Canaan, CT: Keats Publishing (1998), 126-132.
    2. L. Grinspoon et al., "Marihuana: The Forbidden Medicine" (second edition), New Haven, CT: Yale University Press (1997), 186-188.
    3. J. Baron et al. Ulcerative colitis and marijuana. Annals of Internal Medicine 112 (1990): 471.
      [FULL-TEXT]
    4. Mattes RD, Engelman K, Shaw LM, Elsohly MA. 1994. Cannabinoids and appetite stimulation. Pharmacology, Biochemistry and Behavior 49:187-195.
    5. M.R. Tramèr et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ, 323 (2001):16-24
      [PDF] [FULL-TEXT]

    6. P. Consroe and S. Snider, "Therapeutic Potential of Cannabinoids in Neurological Disorders," in Cannabinoids as Therapeutic Agents, ed. R. Mechoulam, Boca Raton, FL: CRC Press (1986), 21-50.
    7. E. Formukon et al. Analgesic and anti-inflammatory activity of constituents of Cannabis Sativa L. Inflammation 12 (1988)

    8. [FULL TEXT]

    9. Pharmos Corporation Press Release, May 21, 1998.
    10. - - - aggiornamenti - - -
      Torna alla pagina precedente

      I CANNABINOIDI 'RAFFREDDANO' L'INTESTINO

      Cannabinoids inhibit motility and secretion in the intestine. They are now assigned the additional task of curbing excessive inflammation, suggesting that drugs targeting the endogenous cannabinoid system could be exploited for inflammatory bowel disease.
      George Kunos & Pál Pacher. Cannabinoids cool the intestine Nature Medicine 10, 678 - 679 (2004)

     

     

      LESIONI MIDOLLARI    

    1. Clendinning, J., "Medicinal Properties of the Cannabis Sativa", in: Med. Chirur. Trans. (London), vol. 26, 1843, p. 188-210.

    2. Mechoulam

    3. Malec J. et al. Cannabis Effect on Spasticity in Spinal Cord Injury. Arch Phys Med Rehabil, vol. 63(3), 1982, pp. 116-118.

    4. Maurer M. et al. Delta-9-tetrahydrocannabinol Shows Antispastic and Analgesic Effects in a Single Case Double-blind Trial. Eur Arch Psychiatry Clin Neurosci, vol. 240(1), 1990, pp. 1-4.

    5. Grotenhermen F, Schnelle M. Survey on the Medical Use of Cannabis and THC in Germany. Journal of Cannabis Therapeutics,Vol.3(2)2003, pp. 17-40

    6. Grotenhermen, F., Huppertz, R., La canapa come medicina, Milano, Leoncavallo, 1999, p. 74

      - - - aggiornamenti - - -

    7. EFFICACIA DEL THC NEL TRATTAMENTO DELLA SPASTICITA' DA LESIONE MIDOLLARE
      Abstract, IACM 2nd Conference on Cannabinoids in Medicine, September 12-13, 2003

     

     
    La bibliografia delle seguenti sezioni:
    ALLERGIE
    ASMA BRONCHIALE
    MALATTIE NEURODEGENERATIVE
    PATOLOGIE CARDIOVASCOLARI
    SINDROMI ANSIOSO-DEPRESSIVE
    SINDROMI DA ASTINENZA
    non e' disponibile sul sito
    Informazioni aggiornate su questi argomenti
    sono disponibili nel capitolo
    Indicazioni terapeutiche di cannabis e cannabinoidi
    in "Erba Medica", edizioni Stampa Alternativa, 2003
       



    http://medicalcannabis.it - bibliografia